Treatment of Hypertension

Canadian Journal of Diabetes

Volumn 37, Issue SUPPL.1, 2013, Pages

  Gilbert, Richard E ^a   Rabi, Doreen ^a   LaRochelle, Pierre ^a   Leiter, Lawrence A ^a   Jones, Charlotte ^a   Ogilvie, Richard ^a   Tobe, Sheldon ^a   Khan, Nadia ^a   Poirier, Luc ^a   Woo, Vincent ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EDUCATION PROGRAM; EVIDENCE BASED MEDICINE; HEALTH EDUCATION; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; META ANALYSIS (TOPIC); MICROALBUMINURIA; PRACTICE GUIDELINE; SYSTOLIC BLOOD PRESSURE; CANADA; DIABETES COMPLICATIONS;

CANADA; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERTENSION;

EID: 84876016615     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.01.033     Document Type: Article

References (16)

1. Campbell N.R., Gilbert R.E., Leiter L.A., et al. Hypertension in people with type 2 diabetes: update on pharmacologic management. Can Fam Physician 2011, 57:997-1002.
2. Cushman W.C., Evans G.W., Byington R.P., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362:1575-1585.
3. Bangalore S., Kumar S., Lobach I., Messerli F.H. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 2011, 123:2799-2810.
4. Reboldi G., Gentile G., Angeli F., et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 2011, 29:1253-1269.
5. Daskalopoulou S.S., Khan N.A., Quinn R.R., et al. The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2012, 28:270-287.
6. Adler A.I., Stratton I.M., Neil H.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000, 321:412-419.
7. Schrier R.W., Estacio R.O., Esler A., Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002, 61:1086-1097.
8. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755-1762.
9. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713. UK Prospective Diabetes Study Group.
10. Cushman W.C., Ford C.E., Cutler J.A., et al. Success and predictors of blood pressure control in diverse north American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002, 4:393-404.
11. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001, 345:851-860.
12. Lindholm L., Ibsen J., Dahlof B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-1010.
13. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153. The Heart Outcomes Prevention Evaluation Study Investigators.
14. Brenner B.M., Cooper M.E., de Zeeuw D., et al. The losartan renal protection study: rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 2000, 1:328-335.
15. Whelton P.K., Barzilay J., Cushman W.C., et al. Clinical Outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005, 165:1401-1409.
16. Weber M.A., Bakris G.L., Jamerson K., et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010, 56:77-85.